Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
Public ClinicalTrials.gov record NCT00452400. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (3 - 4 Doses) Delivered by the Respimat® Inhaler in Patients With COPD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD). The selection of the optimum dose(s) will be based on bronchodilator efficacy (how well it helps your breathing), safety evaluations and pharmacokinetic evaluations (the amount of the medication found in your blood).
Study identification
- NCT ID
- NCT00452400
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 409 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2007 (Type not available)
- Primary completion
- Jan 2008 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 27, 2014
Started 2007
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1222.5.03 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1222.5.07 Boehringer Ingelheim Investigational Site | Lakewood | California | — | — |
| 1222.5.14 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1222.5.13 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1222.5.17 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1222.5.18 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1222.5.15 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 1222.5.04 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1222.5.22 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 1222.5.11 Boehringer Ingelheim Investigational Site | Reno | Nevada | — | — |
| 1222.5.24 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1222.5.12 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1222.5.10 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1222.5.05 Boehringer Ingelheim Investigational Site | Hershey | Pennsylvania | — | — |
| 1222.5.02 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1222.5.08 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1222.5.19 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1222.5.06 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1222.5.21 Boehringer Ingelheim Investigational Site | Kileen | Texas | — | — |
| 1222.5.01 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1222.5.23 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1222.5.20 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00452400, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00452400 live on ClinicalTrials.gov.